Medartis Holding AG
SIX:MED
Medartis Holding AG
Cash & Cash Equivalents
Medartis Holding AG
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Medartis Holding AG
SIX:MED
|
Cash & Cash Equivalents
CHf127.1m
|
CAGR 3-Years
15%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
||
Alcon AG
SIX:ALC
|
Cash & Cash Equivalents
$1.4B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
||
Coltene Holding AG
SIX:CLTN
|
Cash & Cash Equivalents
CHf27.9m
|
CAGR 3-Years
0%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
||
Ypsomed Holding AG
SIX:YPSN
|
Cash & Cash Equivalents
CHf52.3m
|
CAGR 3-Years
24%
|
CAGR 5-Years
17%
|
CAGR 10-Years
11%
|
||
IVF Hartmann Holding AG
SIX:VBSN
|
Cash & Cash Equivalents
CHf72m
|
CAGR 3-Years
53%
|
CAGR 5-Years
24%
|
CAGR 10-Years
14%
|
Medartis Holding AG
Glance View
Medartis Holding AG operates as a medical device company. The company is headquartered in Basel, Basel-Stadt and currently employs 684 full-time employees. The company went IPO on 2018-03-23. The Group develops, manufactures and distributes to surgeons, hospitals and medical centers titanium screws, plates, surgical instruments and system solutions for internal fracture fixation. Medartis AG, the Company's wholly-owned subsidiary, has developed such technologies as TriLock for locking the screw into the plate, SpeedTip, a screw that does not require pre-drilling, and HexaDrive self-holding screw and screw-driver. The company has two product lines. The APTUS product line comprises upper and lower extremities products for hand, wrist, elbow, shoulder and foot fixation. The MODUS line combines products dedicated to cranio-maxillofacial (CMF) surgery. The Group's products are sold globally in more than 30 countries, including Germany and the United States, either directly through its sales subsidiaries, or through third-party distributors.
See Also
What is Medartis Holding AG's Cash & Cash Equivalents?
Cash & Cash Equivalents
127.1m
CHF
Based on the financial report for Jun 30, 2024, Medartis Holding AG's Cash & Cash Equivalents amounts to 127.1m CHF.
What is Medartis Holding AG's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
4%
Over the last year, the Cash & Cash Equivalents growth was 749%. The average annual Cash & Cash Equivalents growth rates for Medartis Holding AG have been 15% over the past three years , 4% over the past five years .